FNDC5 and Myocardial fibrosis: Liu et al. reported that recombinant r-irisin (0.5 or 1.5 g/g body weight/day, I.P.)treatment did not alter blood glucose levels in diabetic mice, but inhibited HG-induced endothelial-mesenchymal transition (EndMT), thereby reducing cardiac fibrosis and left ventricular dysfunction in diabetic mice, whereas high-dose irisin failed to reduce myocardial fibrosis and ventricular dysfunction [31].